Brought to you by 
Novartis partners with KaloBios for antibody humanization
10 Oct 2012
Executive Summary
KaloBios Pharmaceuticals (antibody engineering) has humanized an antibody to an undisclosed target for the Genomics Institute of the Novartis Research Foundation. The two have been collaborating since late 2005, and have now announced a second broader agreement for the development of antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis partners with KaloBios for antibody humanization
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice